INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 35 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $803,000 | -52.2% | 1,250,000 | -55.8% | 0.03% | -48.4% |
| Q4 2020 | $1,681,000 | -14.1% | 2,825,000 | 0.0% | 0.06% | -30.4% |
| Q3 2020 | $1,957,000 | -60.7% | 2,825,000 | -58.6% | 0.09% | -67.4% |
| Q2 2020 | $4,985,000 | +46.2% | 6,825,000 | +78.4% | 0.28% | +4.8% |
| Q1 2020 | $3,410,000 | -45.9% | 3,825,000 | -19.5% | 0.27% | -22.9% |
| Q4 2019 | $6,304,000 | +21.0% | 4,750,000 | -17.4% | 0.35% | +4.2% |
| Q3 2019 | $5,208,000 | -32.5% | 5,750,000 | -25.8% | 0.34% | -24.4% |
| Q2 2019 | $7,713,000 | – | 7,750,000 | – | 0.44% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 55,943,000 | $39,071,000 | 2.11% |
| PenderFund Capital Management Ltd. | 5,000,000 | $4,719,000 | 1.31% |
| Opti Capital Management, LP | 13,246,000 | $9,340,000 | 1.14% |
| Context Partners Fund, L.P. | 7,485,000 | $5,145,000 | 1.12% |
| Context Capital Management, LLC | 7,485,000 | $5,145,000 | 1.12% |
| Soros Fund Management | 19,552,000 | $13,548,000 | 0.33% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 18,604,000 | $12,963,000 | 0.29% |
| Senvest Management, LLC | 5,000,000 | $3,465,000 | 0.20% |
| CSS LLC/IL | 2,825,000 | $1,957,000 | 0.09% |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 350,000 | $243,000 | 0.04% |